KERATIN BD-10, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Abstract

The present invention provides a keratin BD-10, an encoding nucleic acid molecule, an expression vector, a host cell thereof, a preparation method for BD-10, and a pharmaceutical composition containing the keratin BD-10. Also provides the use of the keratin BD-10, nucleic acid molecule, expression vector, host cell or pharmaceutical composition in the preparation of medicament for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

Claims

1. A keratin BD-10, wherein the amino acid sequence of the keratin BD-10 is: (1) the amino acid sequence set forth in SEQ ID NO:1 in the sequence listing; (2) an amino acid sequence that basically maintains the same biological function formed by substitution, deletion or addition of 1-35 amino acids to the amino acid sequence set forth in SEQ ID NO:1 in the sequence listing.

2. The keratin BD-10 of claim 1, wherein the keratin BD-10 may have a conventional modification; or the keratin BD-10 is further linked with a tag for detection or purification.

3. The keratin BD-10 of claim 2, wherein the conventional modification includes acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, polyethylene glycol PEG modification, immobilization modification, sulfation, oxidation, methylation, deamination, formation of disulfide bond or breakage of disulfide bond; the tag includes His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc, Profinity eXact.

4. A nucleic acid molecule encoding the keratin BD-10 of claim 1.

5. The nucleic acid molecule of claim 4, wherein the nucleotide sequence of the nucleic acid molecule is: (1) the nucleotide sequence set forth in SEQ ID NO:2 in the sequence listing; (2) a nucleotide sequence obtained by sequence optimization based on the nucleotide sequence set forth in SEQ ID NO:2; (3) a nucleotide sequence complementary to the nucleotide sequence in (1) or (2) above.

6. An expression vector, wherein the expression vector contains the nucleic acid molecule of claim 4.

7. A host cell, wherein the host cell contains the expression vector of claim 6 or the nucleic acid molecule of claim 4 integrated into the genome.

8. The host cell of claim 7, wherein the host cell includes bacteria, yeast, Aspergillus, plant cells, or insect cells.

9. The host cell of claim 8, wherein the bacteria includes Escherichia coli.

10. A method for preparing the keratin BD-10 of claim 1, wherein the method comprises the following steps: A. synthesizing a nucleic acid molecule corresponding to the keratin BD-10 of claim 1, linking the nucleic acid molecule to a corresponding expression vector, transforming the expression vector into a host cell, and culturing the host cell with the expression vector in a fermentation device under certain conditions and inducing the expression of the keratin BD-10 to obtain a crude protein solution containing the keratin BD-10; B. subjecting the crude protein solution obtained in step A to separation and purification, and drying to obtain the keratin BD-10.

11. The method of claim 10, wherein in step A, the host cell is mainly selected from Escherichia coli, the keratin BD-10 is expressed in the inclusion bodies of Escherichia coli, and the fermentation device includes shake flask or fermenter.

12. The method of claim 10, wherein in step A, after inducing the expression of the keratin BD-10, impurities in which may be removed with a cleaning agent to obtain the crude protein solution by dissolving in a solution.

13. The method of claim 10, wherein in step B, the separation and purification method includes ultrafiltration microfiltration membrane technology purification method, column chromatography purification method, salting out method, and dialysis method.

14. A pharmaceutical composition, wherein the pharmaceutical composition contains the keratin BD-10 of claim 1 and a pharmaceutically acceptable carrier or excipient.

15. A method of antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, antihypertension, antiinflammatory, antiviral in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the keratin BD-10 of claim 1 or the nucleic acid molecule of claim 4 or the expression vector of claim 6 or the host cell of claim 7 or the pharmaceutical composition of claim 14.

Description

DRAWINGS

[0107] FIG. 1: Analysis of reduced SDS polyacrylamide gel electrophoresis (SDS-PAGE) of expressed protein BD-10.

[0108] (M: Protein molecular weight standard; S: Expressed protein BD-10)

[0109] FIG. 2: Effect of protein BD-10 on lipopolysaccharide (LPS) induced fever in rats.

[0110] (Compared with normal control group, *** P<0.001; Compared with the model group, ##P<0.01, ###P<0.001)

[0111] FIG. 3: Effect of protein BD-10 on yeast-induced fever model in rats.

[0112] (Compared with normal control group, ** P<0.01, *** P<0.001; Compared with the model group, #P<0.05, ##P<0.01, ###P<0.001).

DETAILED EMBODIMENTS

[0113] The following examples and pharmacological activity test examples are used to further illustrate the present invention, but this does not mean any limitation to the present invention.

[0114] The experimental methods in the following examples and pharmacological activity test examples are conventional methods unless otherwise specified; the experimental materials used, unless otherwise specified, are purchased from conventional biochemical reagent companies.

Example 1 Shake Flask Fermentation to Prepare Protein BD-10 Crude Solution A (TB Medium)

[0115] Synthesize the nucleotide sequence set forth in SEQ ID NO:2 and transfer it into the pET-28a(+) vector; confirm the sequence to obtain an expression vector containing the correct sequence; transfect the expression vector into BL21 (DE3) cells, obtain expression competent host cells containing the target nucleotide sequence. Add LB medium and incubate in a shaker at 37° C. and 220 rpm for 1 hour to obtain a recombinant strain.

[0116] Dip the recombinant strain and streak it on an LBA plate containing Kanamycin, and place the plate upside down in a 37° C. constant temperature incubator overnight for 16 hours.

[0117] Configure 400 ml of TB medium, divided into 2 bottles, each bottle of 200 ml. Add Kanamycin (final concentration 50 μg/ml) to each bottle (200 ml) of TB medium. Take a single colony on the plate and add it to the TB medium. Amplify and culture overnight at 37° C. and 220 rpm to obtain seed liquid in the shaker.

[0118] Configure 28.8 L TB medium, divided into 144 bottles, each bottle of 200 ml. Add Kanamycin (final concentration 50 μg/ml) to each bottle (200 ml) of TB medium, then add 2 ml of seed solution, and incubate in a shaker at 37° C. and 220 rpm for 2-3 hours. Monitor the OD.sub.600, when the OD.sub.600 reaches about 1.0, add an inducer to induce protein expression in the shaker, and the induction conditions are selected from the following table.

TABLE-US-00001 Induction Induction Shaker Inducer temperature time speed Induction IPTG(Final 16° C. 16 h  220 rpm conditions concentration 25° C. 8 h 0.5 mM) 37° C. 5 h

[0119] Combine each bottle of bacterial liquid, centrifuge at 7000 rpm for 5 minutes, and discard the supernatant after sterilization; the precipitate is suspended in about 3 L of buffer, filtered with an 80-100 mesh screen, and the filtrate is crushed with a high-pressure crusher at a pressure of 800-1000 bar, twice, 2 minutes each time. Centrifuge the broken bacteria liquid at 7000 rpm for 30 minutes, discard the supernatant, and obtain the precipitate (ie inclusion body). The precipitate was washed twice with 1 L detergent, centrifuged and the supernatant was discarded. The precipitate was dissolved in urea solution 4 times, respectively, 800 ml, 600 ml, 400 ml and 400 ml. The four solutions were combined and centrifuged at 7000 rpm for 30 minutes. The precipitate was discarded and the supernatant was the crude protein solution A.

TABLE-US-00002 Buffer cleaning agent Urea solution buffer 2M urea solution (may 8M urea solution (may A contain Triton) contain Tris/HCl buffer 4M urea solution (may or NaH.sub.2PO.sub.4/Na.sub.2HPO.sub.4 Buffer) contain Triton) 4M urea solution (may 2M Guanidine Hydrochloride contain Tris/HCl buffer) Solution 4M Guanidine Hydrochloride Solution

[0120] Protein BD-10 crude solution A was analyzed by reduced SDS-PAGE. The separation gel concentration was 12.5% and then stained with Coomassie brilliant blue 8250 method; a clear blue band is shown near the molecular weight of 55 kD.

Example 2 Shake Flask Fermentation to Prepare Protein BD-10 Crude Solution B (Other Medium)

[0121] In Example 1, it was synthesized and sequenced to confirm that an expression vector containing the sequence set forth in SEQ ID NO:2 was obtained; the expression vector was transfected into Transetta (DE3) cells to obtain expression-competent host cells containing the target nucleotide sequence.

[0122] Prepare 20 ml of LB medium, take 800 μl, add 50 μl of host cells containing the target coding sequence, and incubate at 37° C. and 220 rpm for 1 hour in a shaker.

[0123] Dip the above bacterial liquid and streak it on an LBA plate containing Kanamycin, and place the plate upside down in a 37° C. constant temperature incubator overnight for 16 hours.

[0124] Take 10 ml of LB medium, add Kanamycin (final concentration 50 μg/ml), take a single colony on the plate and add it to the LB medium. Amplify and culture overnight at 37° C. and 220 rpm for 15 hours to obtain seed liquid in a shaker.

[0125] Configure 1 L of the medium shown in the table below, and divide it into 10 bottles of 100 ml each. Add Kanamycin (final concentration 50 μg/ml) to each bottle (100 ml) of medium and then add 1 ml of seed solution. Incubate at 37° C. and 220 rpm for 2-3 hours in a shaker. Monitor OD.sub.600 and add inducer IPTG (final concentration 0.5 mM) when OD.sub.600 reaches about 1.0. Induce protein expression at 37° C. and 220 rpm in a shaker.

TABLE-US-00003 Culture medium LB medium, SOB medium, SOC medium

[0126] Combine each bottle of bacterial liquid, centrifuge at 10000 rpm for 10 minutes, and discard the supernatant after sterilization; the precipitate is suspended in about 100 mL of buffer, filtered with an 80-100 mesh screen, and the filtrate is crushed with a high-pressure crusher at a pressure of 800-1000 bar, twice, 2 minutes each time. Centrifuge the broken bacteria liquid at 10000 rpm for 30 minutes and discard the supernatant.

[0127] Add 40 mL of cleaning agent buffer A to the precipitate for washing 3 times, centrifuge and discard the supernatant; Add 40 mL of cleaning agent 2M urea solution to the precipitate to wash twice, centrifuge, and discard the supernatant; the precipitate is then added to 8M urea solution (containing 50 mM Tris/HCl buffer) to dissolve 3 times, respectively, 40 ml, 30 ml, 30 ml; the combined solutions were centrifuged at 7000 rpm for 30 minutes, the precipitate was discarded, and the supernatant was the crude protein solution B.

[0128] Protein BD-10 crude solution B was analyzed by reduced SDS-PAGE with the separation gel concentration was 12.5% and then stained with Coomassie brilliant blue 8250 method; a clear blue band is shown near the molecular weight of 55 kD.

Example 3 Preparation of Crude Protein BD-10 Solution C in a Fermenter

[0129] In Example 1, it was synthesized and sequenced to confirm that an expression vector containing the sequence set forth in SEQ ID NO:2 was obtained; the expression vector was transfected into BL21 (DE3) cells to obtain expression-competent host cells containing the target nucleotide sequence. Add the expression-competent host cells in LB medium and incubate in a shaker at 37° C. and 220 rpm for 1 hour to obtain a recombinant strain.

[0130] In the LBA plate containing Kanamycin, add 100 μl of the recombinant strain, spread with spreader until it becomes evenly dry, and place the plate upside down in a constant temperature incubator at 37° C. for overnight culture. Take three single colonies, streak them on a plate containing Kanamycin, and then culture the plate overnight. After three batches of shake flask fermentation and expression verification are confirmed to be correct, the strains are preserved with 15% glycerol and divided into 0.8 ml each to obtain a working cell bank, which is stored in a refrigerator at −80° C. for later use.

[0131] Take out 1 glycerol bacteria from the working cell bank, take 100 μl, and add it to 40 ml LB medium, add Kanamycin (final concentration 50 μg/ml), incubate in a shaker at 37° C. and 220 rpm for 6 hours to obtain a first-level seed solution.

[0132] Take 1.2 ml of the first-level seed solution, add it to 120 ml LB medium, add Kanamycin (final concentration 50 μg/ml), and then incubate in a shaker at 37° C. and 220 rpm for 6 hours to obtain a second-level seed solution.

[0133] Add 3 L of modified LB broth to a 5 L fermenter, then add 120 ml of the second-level seed solution, 3 ml of Kanamycin (final concentration 50 μg/ml), and incubateat 37° C. and 30% dissolved oxygen (series speed) for about 8 hours. Monitor the OD value around 20 and 3 g lactose as an inducer. Induction was performed at 20° C., fed at a rate of 30 ml/hour, and incubated at 20° C. for 24 hours.

[0134] Centrifuge the bacterial solution at 7000 rpm for 5 minutes, and discard the supernatant after sterilization; the precipitate is suspended in about 200 mL of buffer A, filtered with an 80-100 mesh screen, and the filtrate is crushed with a high-pressure crusher at a pressure of 800-1000 bar, twice, 2 minutes each time. Centrifuge the broken bacteria liquid at 7000 rpm for 30 minutes and discard the supernatant.

[0135] Add 2M urea solution (including 1% Triton) to the precipitate and wash it twice, 1 L each time; then add 1 L 2M urea solution to wash once, centrifuge and discard the supernatant. The precipitate is then added to 8M urea solution (containing 50 mM Tris/HCl buffer) to dissolve 4 times, respectively, 400 ml, 300 ml, 200 ml, 100 ml; the four solutions were combined, centrifuged at 7000 rpm for 30 minutes, the precipitate was discarded, and the supernatant was the crude protein solution C.

[0136] Protein BD-10 crude solution C was analyzed by reduced SDS-PAGE with the separation gel concentration was 12.5% and then stained with Coomassie brilliant blue R250 method; a clear blue band is shown near the molecular weight of 55 kD.

Example 4 Protein BD-10 was Prepared from Crude Protein Solution a by Dialysis

[0137] The crude protein solution A obtained in Example 1 was filtered with a 0.55 μm filter membrane, and the filtrate was combined. The filtrate was dialyzed with water, the molecular weight cut-off of the dialysis bag was 10 kD, dialyzed for 72 hours, and the inner liquid was freeze-dried to obtain the target protein BD-10; the purity measured by electrophoresis was 96.8%.

[0138] Confirmation of Protein BD-10 Structure:

[0139] 1, Reduced SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis

[0140] Instrument: Protein electrophoresis (Bio-Rad).

[0141] Methods and results: The protein BD-10 solution was analyzed by reduced SDS-PAGE, the separation gel concentration was 12.5%, and it was stained with Coomassie brilliant blue R250 method. The molecular weight of BD-10 band is around 55 kD.

[0142] 2, Complete protein sequence analysis based on LC-MS/MS

[0143] Main materials: Acetonitrile, formic acid, ammonium bicarbonate, dithiothreitol (DTT), iodoacetamide (IAA), trypsin, chymotrypsin, Glu-C, Asp-N;

[0144] Main instruments: Capillary High Performance Liquid Chromatograph (Thermo Ultimate 3000), Electrospray-Combined Ion Trap Orbitrap Mass Spectrometer (Thermo Q Exative Hybrid Quadrupole-Orbitrap Mass Spectrometer).

[0145] Methods and Results:

[0146] Protein BD-10 undergoes pre-treatments such as dissolution replacement, reductive alkylation, and various proteolysis to obtain enzyme-cleaved peptides; Restriction digestion peptide solution was analyzed by liquid chromatography tandem mass spectrometry. The original mass spectrometry file uses Maxquant (1.6.2.10) to search the protein database to analyze the data. The identification result was determined to be consistent with the target sequence SEQ ID NO:1.

Example 5 Protein Crude Solution A is Purified by Other Methods to Prepare Protein BD-10

[0147] The crude protein solution A obtained in Example 1 was purified by the following two methods:

[0148] The first method: salting out;

[0149] The crude protein solution A is placed in a stirred container for two salting out: Slowly add saturated ammonium sulfate solution along the wall to make the final concentration of ammonium sulfate 25% or 50%. During the salting-out process, the protein is separated out. After the salting-out is complete, filter to complete the first salting-out; Add 400 ml of pure water to the precipitate to suspend, and then slowly add a saturated solution of ammonium sulfate along the wall to make the final concentration of ammonium sulfate 25%. Carry out the second salting out, filtration, and the precipitate is the crude protein extract. The crude protein extract was washed three times with water: add 200 ml of pure water to suspend, stir, let stand, and filter; After this is repeated three times, the precipitate is freeze-dried to obtain the target protein BD-10.

[0150] The second method: column chromatography;

[0151] The crude protein solution A is purified by anion exchange resin column, such as HiTrap Q FF 16/10, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE, etc. The eluent is a gradient elution of NaCl solution, plus 20 mM NaH.sub.2PO.sub.4/Na.sub.2HPO.sub.4 buffer (pH 8.0). The elution fractions are combined according to the results of SDS-PAGE electrophoresis detection. The combined eluate was centrifuged twice at 7000 rpm for 1 hour each time; The supernatant was filtered with a 0.45 μm filter membrane, and the filtrates were combined. The filtrates are concentrated by dialysis with water, the molecular weight cut-off of the dialysis bag is 10 kD, and the inner liquid is freeze-dried to obtain the target protein BD-10.

[0152] The product protein BD-10 obtained by the two methods was confirmed to have the same amino acid sequence as the protein prepared in Example 4 through the same structural confirmation method as in Example 4.

Example 6 Protein BD-10 was Prepared by Purified Protein Crude Solution B

[0153] The crude protein solution B obtained in Example 2 was purified by the following three methods:

[0154] The First Method: Dialysis;

[0155] The crude protein solution B is filtered with a 0.45 μm membrane, the filtrate is dialyzed with water, dialyzed for more than 72 hours, and the inner solution is freeze-dried to obtain the target protein BD-10.

TABLE-US-00004 Dialysis bag Molecular weight cut-off: 0.5 kD, 3.5 kD, 5 kD, 10 kD

[0156] The Second Method: Column Chromatography;

[0157] The crude protein solution B is purified by anion exchange resin column, such as HiTrap Q FF 16/10, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE, etc. The eluent is a gradient elution of NaCl solution, plus 20 mM NaH.sub.2PO.sub.4/Na.sub.2HPO.sub.4 buffer (pH 8.0). The elution fractions are combined according to the results of SDS-PAGE electrophoresis detection. The combined eluate was centrifuged twice at 7000 rpm for 1 hour each time; The supernatant was filtered with a 0.45 μm filter membrane, and the filtrates were combined. The filtrates are concentrated by dialysis with water, the molecular weight cut-off of the dialysis bag is 10 kD, and the inner liquid is freeze-dried to obtain the target protein BD-10.

[0158] The third method: salting out;

[0159] The crude protein solution B is placed in a stirred container for two salting out: Slowly add saturated ammonium sulfate solution along the wall to make the final concentration of ammonium sulfate 25% or 50%. During the salting-out process, the protein is separated out. After the salting-out is complete, filter to complete the first salting-out; Add 400 ml of pure water to the precipitate to suspend, and then slowly add a saturated solution of ammonium sulfate along the wall to make the final concentration of ammonium sulfate 25%. Carry out the second salting out, filtration, and the precipitate is the crude protein extract. The crude protein extract was washed three times with water: add 200 ml of pure water to suspend, stir, let stand, and filter; After this is repeated three times, the precipitate is freeze-dried to obtain the target protein BD-10.

[0160] The product protein BD-10 obtained by the three methods was confirmed to have the same amino acid sequence as the protein prepared in Example 4 through the same structural confirmation method as in Example 4.

Example 7 Protein BD-10 was Prepared by Purification of Crude Protein Solution C

[0161] The crude protein solution C obtained in Example 3 was purified by the following two methods:

[0162] The First Method: Microfiltration Membrane Technology;

[0163] The crude protein solution C is purified by microfiltration membrane technology: first use a 1500 nm or 1000 nm ceramic membrane core for solid-liquid separation; discard the inner liquid, and then use a 20 nm or 50 nm ceramic membrane core for repeated microfiltration to remove urea; The inner liquid of the second microfiltration is freeze-dried to obtain the target protein BD-10.

[0164] The Second Method: Salting Out;

[0165] The crude protein solution C was placed in a container with stirring for two salting out: Slowly add saturated ammonium sulfate solution along the wall to make the final concentration of ammonium sulfate 25%. During the salting-out process, the protein is separated out. After the salting-out is complete, filter to complete the first salting-out; Add 400 ml of pure water to the precipitate to suspend, and then slowly add a saturated solution of ammonium sulfate along the wall to make the final concentration of ammonium sulfate 25%. Carry out the second salting out, filtration, and the precipitate is the crude protein extract. The crude protein extract was washed three times with water: add 200 ml of pure water to suspend, stir, let stand, and filter; After this is repeated three times, the precipitate is freeze-dried to obtain the target protein BD-10.

[0166] The product protein BD-10 obtained by the two methods was confirmed to have the same amino acid sequence as the protein prepared in Example 4 through the same structural confirmation method as in Example 4.

[0167] Pharmacological Test

Experimental Example 1 the Pharmacodynamic Test of Protein BD-10 (Example 4 Protein) on Lipopolysaccharide (LPS) Induced Fever in SD Rats

[0168] Animals: 230-260 grams of male SD rats;
Drugs: lipopolysaccharide (LPS, SIGMA L-2880), aspirin (SIGMA A2093), protein BD-10;
Instruments: electronic balance (SARTORIUS BP121S type), electronic clinical thermometer (CITIZEN CT-513W type).

[0169] Experiment Grouping:

[0170] Normal Control Group;

[0171] Model group: lipopolysaccharide fever model;

[0172] Positive control group: Aspirin 300 mg/kg group;

[0173] Protein BD-10, 10 mg/kg group, 50 mg/kg group.

Method: the method of intraperitoneal injection of Lipopolysaccharide to replicate rat fever model.

[0174] Preparation of experimental animals: After the experimental animals adapt to the experimental environment (temperature 22° C.±2° C., relative humidity 50%±2%) for 1 day. Pre-adaptation to measure rectal temperature at 8:00 and 15:00, rats were fasted and water was taken freely 12 h before experiment, and let the animal to empty its feces before measuring the rectal temperature. Apply petroleum jelly to the electronic thermometer probe before each temperature measurement. Insert the rat rectum 2 cm (can be marked at 2 cm to ensure that the depth of each insertion is consistent), and record the body temperature after the reading is stable.

[0175] Intraperitoneal injection of lipopolysaccharide to replicate rat fever model: The body temperature of the rats was measured before modeling. Qualified rats with a body temperature of 36.2-37.3° C. were selected and randomly divided into groups with 8 rats in each group. After oral administration of aspirin and different doses of protein BD-10, lipopolysaccharide (20 μg/kg, 2 ml/kg) was injected intraperitoneally immediately, and the normal control group was injected intraperitoneally with an equal volume of normal saline. The body temperatures of the rats were monitored after 2 hours for a total of 8 hours.

Statistics:

[0176] According to the body temperature measured at each time point on the day of the experiment, calculate the mean, standard deviation and standard error of the body temperature of each group of rats. The data of each group was compared with TTEST, and P<0.05 was considered as a significant difference.

[0177] Experimental Results:

[0178] Immediately after oral administration of aspirin (300 mg/kg), protein BD-10 (10 mg/kg, 50 mg/kg), intraperitoneal injection of 20 μg/kg lipopolysaccharide was performed to establish a model. The animal body temperature was monitored at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. The results are shown in Table 1 and FIG. 2.

TABLE-US-00005 TABLE 1 Effects of test drugs on lipopolysaccharide (LPS) induced fever model in rats Body Body Body Body temperature 2 temperature 4 temperature 6 temperature 8 Basal body hours after hours after hours after hours after temperature modeling modeling modeling modeling Group N (° C.) (° C.) (° C.) (° C.) (° C.) Normal 8 36.9 ± 0.1 36.7 ± 0.1   36.8 ± 0.05   36.6 ± 0.05 36.7 ± 0.03  control group Model 8 36.8 ± 0.1 37.6 ± 0.1*** 37.8 ± 0.1***   37.8 ± 0.2*** 37.8 ± 0.2*** group Positive 8 36.9 ± 0.1 36.8 ± 0.1### 36.9 ± 0.2###  36.8 ± 0.2## 36.9 ± 0.1### control group BD-10-10 8 36.8 ± 0.1 37.3 ± 0.1#  37.8 ± 0.1   37.8 ± 0.1 37.6 ± 0.1   mg/kg BD-10-50 8 36.9 ± 0.1 37.3 ± 0.2   37.7 ± 0.2   37.9 ± 0.2 37.6 ± 0.1   mg/kg (Compared with the normal control group, ***P < 0.001; compared with the model group, #P < 0.05, ##P < 0.01, ###P < 0.001)

Experimental Results:

[0179] Immediately after oral administration of aspirin (300 mg/kg), protein BD-10 (10 mg/kg, 50 mg/kg), respectively, intraperitoneal injection of 20 μg/kg lipopolysaccharide was performed to establish a model. The animal body temperature was monitored at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. The results show that:

[0180] 1) Intraperitoneal injection of 20 μg/kg lipopolysaccharide can successfully induce the increase of body temperature in rats. The body temperature of rats in the model group increased significantly at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. Compared with the normal group, P<0.05, there is a statistical difference, and the model is stable.

[0181] 2) The positive tool drug aspirin group can effectively inhibit the increase in body temperature of model rats at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. Compared with the model group, P<0.05, there is a statistical difference, and the performance of positive tool drugs is relatively stable.

[0182] 3) Protein BD-10 10 mg/kg dose group can significantly reduce the body temperature of model rats 2 hours after modeling, and compared with the model group, P<0.05, there is a statistical difference.

Experimental Example 2 the Pharmacodynamic Test of Protein BD-10 (the Protein in Example 4) on the Fever Model of SD Rats Induced by Yeast

[0183] Animals: 230-260 grams of male SD rats;
Medicines: yeast (OXOID LP0021), aspirin (SIGMA A2093), protein BD-10;
Instruments: electronic balance (SARTORIUS BP121S type), electronic clinical thermometer (CITIZEN CT-513W type).
Experiment grouping: [0184] Normal control group; [0185] Model group: yeast fever model; [0186] Positive control group: Aspirin 300 mg/kg group; [0187] Protein BD-10, 10 mg/kg group, 50 mg/kg group.

Method:

[0188] Preparation of experimental animals: After the experimental animals adapt to the experimental environment (temperature 22° C.±2° C., relative humidity 50%±2%) for 1 day. Pre-adaptation to measure rectal temperature at 8:00 and 15:00, rats were fasted and water was taken freely 12 h before experiment, and let the animal to empty its feces before measuring the rectal temperature. Apply petroleum jelly to the electronic thermometer probe before each temperature measurement. Insert the rat rectum 2 cm (can be marked at 2 cm to ensure that the depth of each insertion is consistent), and record the body temperature after the reading is stable.

[0189] Subcutaneous injection of dry yeast to replicate rat fever model: The body temperature of the rats was measured before modeling. Qualified rats with a body temperature of 36.2-37.3° C. were selected and randomly divided into groups with 8 rats in each group. After oral administration of aspirin and different doses of protein BD-10, 20% yeast suspension (10 ml/kg) was injected subcutaneously immediately, and the normal control group was injected intraperitoneally with an equal volume of normal saline. The body temperatures of the rats were monitored after 2 hours for a total of 8 hours.

Statistics:

[0190] According to the body temperature measured at each time point on the day of the experiment, calculate the mean, standard deviation and standard error of the body temperature of each group of rats. The data of each group was compared with TTEST, and P<0.05 was considered as a significant difference.

Experimental Results:

[0191] Immediately after oral administration of aspirin (300 mg/kg), protein BD-10 (10 mg/kg, 50 mg/kg), subcutaneous injection of 20% yeast was performed to establish a model. The animal body temperature was monitored at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. The results are shown in Table 2 and FIG. 3.

TABLE-US-00006 TABLE 2 Effects of the tested drugs on the yeast-induced fever model in rats Body Body Body Body temperature 2 temperature 4 temperature 6 temperature 8 Basal body hours after hours after hours after hours after temperature modeling modeling modeling modeling Group N (° C.) (° C.) (° C.) (° C.) (° C.) Normal 8 36.6 ± 0.1 36.6 ± 0.1  36.7 ± 0.1   36.6 ± 0.1   36.5 ± 0.04  control group Model 8 36.7 ± 0.1  37.5 ± 0.1*** 37.7 ± 0.1*** 37.7 ± 0.1*** 37.6 ± 0.1*** group Positive 8 36.7 ± 0.1 37.0 ± 0.1## 37.0 ± 0.1### 37.0 ± 0.1### 37.0 ± 0.1### control group BD-10-10 8 36.7 ± 0.1  36.8 ± 0.05### 37.2 ± 0.1### 37.4 ± 0.1   37.5 ± 0.1   mg/kg BD-10-50 8  36.6 ± 0.04 37.0 ± 0.1## 37.4 ± 0.04## 37.4 ± 0.01#  37.4 ± 0.09## mg/kg (Compared with the normal control group, **P < 0.01, ***P < 0.001; compared with the model group, #P < 0.05, ##P < 0.01, ###P < 0.001)

Experimental Results:

[0192] Immediately after oral administration of aspirin (300 mg/kg) and protein BD-10 (10 mg/kg, 50 mg/kg), subcutaneous injection of 20% yeast was performed to establish a model. The animal body temperature was monitored at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. The results show that:

[0193] 1) The body temperature of rats in the model group increased significantly at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. Compared with the normal group, P<0.05, which was statistically different. The model was successfully established and was stable and reliable.

[0194] 2) The positive tool drug aspirin group can effectively inhibit the increase in body temperature of model rats at 2 hours, 4 hours, 6 hours, and 8 hours after modeling. Compared with the model group, P<0.05, there is a statistical difference, and the performance of positive tool drugs is relatively stable.

[0195] 3) Different doses of protein BD-10 can inhibit the increase in body temperature of model rats to varying degrees after modeling, and have a strong effect. At most of the time points after modeling, the body temperature of the model rats can be inhibited, and compared with the model group, P<0.05, which is statistically different.

Experimental Example 3 the Pharmacodynamic Test of Protein BD-10 (Example 4 Protein) on Convulsive Epilepsy in Mice Caused by the Convulsion Agent Pilocarpine (PLO)

[0196] Animals: male ICR mice;
Drugs: Pilocarpine HCl (PLO, pilocarpine, pilocarpine hydrochloride), Diazepam (diazepam tablets), protein BD-10.

[0197] Experiment grouping: [0198] Model group: [0199] Diazepam 2 mg/kg group; [0200] Protein BD-10, 50 mg/kg group, 200 mg/kg group.

Method:

Model Preparation and Administration:

[0201] The drug was administered once in the afternoon the day before modeling, PLO-225 mg/kg (modeling agent) was injected intraperitoneally 1 hour after the test drug was administered intragastrically on the day of modeling. And positive drug can be administered once 20 minutes before modeling. Observe for 30 minutes after PLO injection.

[0202] Observation indicators: {circle around (1)}Seizure situation: the time of seizures from Grade II to Grade IV; {circle around (2)}the time to death.

[0203] Seizure grade: Refer to Racine grading standard: Grade 0: No response; Grade I: manifested as twitching of facial muscles or the corners of the mouth; Grade II: can nod; Grade III: twitching of one limb; Grade IV: rigidity or body twitching; Grade V: generalized epilepsy (generalized tonic seizures).

Data Processing:

[0204] Count the number of Grade IV seizures and deaths in each group of mice in the experiment; Grade II, III and IV incubation period. The incubation period of mice that did not attack to Grade IV was recorded as a maximum of 1800 seconds. Chi-square test was used for statistics of the number of cases. The mean value and standard error of the incubation period were calculated, and TTEST was used to compare the model group with other groups. P<0.05 was considered as a significant difference.

Experimental Results: See Table 3 and Table 4.

[0205]

TABLE-US-00007 TABLE 3 Experiments of tested drugs on PLO-induced epilepsy in mice-statistics of cases Cases of Grade IV Cases mor- exper- Cases of seizure of tality Group iment Grade IV rate deaths rate Model group 10 8 80% 0 0 Diazepam 2 mg/kg 10  0** 0** 0 0 BD-10-50 mg/kg 10 9 90% 0 0 BD-10-200 mg/kg 10 7 70% 0 0 (Compared with the model group, *P < 0.05, **P < 0.01)

TABLE-US-00008 TABLE 4 Experiments of tested drugs on PLO-induced epilepsy in mice-Grade II, Grade III and Grade IV seizures incubation period (mean ± SEM) Grade II Grade III Grade IV seizure seizure seizure incubation incubation incubation Group period (s) period (s) period (s) Model group 86 ± 5 142 ± 6 894 ± 164 Diazepam 2 mg/kg 109 ± 8*  182 ± 14* 1800 ± 0**  BD-10-50 mg/kg 93 ± 4  166 ± 8* 871 ± 144 BD-10-200 mg/kg 90 ± 6 151 ± 7 918 ± 198 (Compared with the model group, *P < 0.05, **P < 0.01)

Experimental Results:

[0206] 1) Experimental results show that the rate of Grade IV seizure in the model group is 80%. None of the 40 mice died. [0207] 2) Positive drugs can completely suppress the rate of Grade IV epileptic seizure and significantly prolong the epileptic seizure incubation period of Grade II, III and IV in mice. [0208] 3) In the comparison of the incubation period of epilepsy Grade III, the BD-10 50 mg/kg dose group was statistically different from the model group.

Experimental Example 4 Efficacy Test of Protein BD-10 (Example 4 Protein) on Pentylenetetrazole (PTZ)-Induced Epilepsy in Mice

[0209] Animals: male ICR mice;

Medicines: Pentylenetetrazol (PTZ), Retigabine, Protein BD-10.

[0210] Experiment grouping: [0211] Model group; [0212] Retigabine 60 mg/kg group; [0213] Protein BD-10, 50 mg/kg group, 200 mg/kg group;

Method:

Model Preparation and Administration:

[0214] The drug was administered once in the afternoon the day before modeling, On the day of modeling, PTZ-65 mg/kg (modeling agent) was injected intraperitoneal 1 hour after the test drug was administered intragastrically, and the positive drug can be administered once half an hour before modeling. Continue to observe for 15 minutes after injection of PTZ.

[0215] Observation index: {circle around (1)}Seizure situation: the time of seizures from Grade III to Grade VI; {circle around (2)}Death situation

[0216] Seizure grade: Refer to Racine grading standard: Grade 0: No response; Grade I: manifested as twitching of facial muscles or the corners of the mouth; Grade II: can nod; Grade III: twitching of one limb; Grade IV: rigidity or body twitching; Grade V: generalized epilepsy (generalized tonic seizures).

Data Processing:

[0217] Count the cases of seizures and deaths in each group of mice in the experiment; Grade III and IV incubation period. The incubation period of mice that have not attacked to Grade IV is recorded as the maximum of 900 seconds. Chi-square test was used for statistics of the number of cases. Calculate the mean and standard error of the incubation period. Use TTEST to compare the model group with other groups, and P<0.05 is considered as a significant difference. Experimental results: see Table 5 and Table 6.

TABLE-US-00009 TABLE 5 Test drug on PTZ-induced epilepsy in mice-statistics of cases Cases of Grade IV Cases mor- exper- Cases of seizure of tality Group iment Grade IV rate deaths rate Model group 10 9 90% 1 10% Retigabine 60 10  2**  20%** 0 0 mg/kg BD-10-50 mg/kg 10 8 80% 0 0 BD-10-200 mg/kg 10 7 70% 0 0 (Compared with the model group, *P < 0.05, **P < 0.01)

TABLE-US-00010 TABLE 6 Experiment of the test drug on PTZ-induced epilepsy in mice-the incubation period of Grade III and IV seizures (mean ± SEM) Grade III seizure Grade IV seizure Group incubation period (s) incubation period (s) Model group 63 ± 6 185 ± 84  Retigabine 60 mg/kg  83 ± 7*  745 ± 103** BD-10-50 mg/kg 63 ± 2 296 ± 106 BD-10-200 mg/kg 81 ± 9 359 ± 120 (Compared with the model group, *P < 0.05, **P < 0.01)

Experimental Results:

[0218] 1) The experimental results showed that the rate of Grade IV seizure in the model group was 90%. Two of the 40 mice died. [0219] 2) Positive drugs can significantly reduce the rate of Grade IV epileptic seizure, and significantly prolong the incubation period of Grade III and IV seizures in mice. [0220] 3) In the comparison of the incubation period of Grade IV epilepsy, the BD-10 has a tendency to extend the incubation period, but due to the large standard error, there is no statistical difference compared with the model group.

Experimental Example 5 the Pharmacodynamic Test of Protein BD-10 (Example 4 Protein) on the Expectorant of Phenol Red Excretion Method in Mice

[0221] Animals: male ICR mice;
Drugs and reagents: Mucosolvan (ambroxol hydrochloride tablets), phenol red, sodium bicarbonate, protein BD-10;
Instruments: centrifuge (Sigma-3K15 type), balance (XS105DU type), Microplate tester (BIO-TEK type).
Experiment grouping: [0222] Solvent control group; [0223] Mucosolvan 30 mg/kg group; [0224] Protein BD-10, 20 mg/kg group, 50 mg/kg group.

Method:

Model Preparation and Administration:

[0225] The animals were fasted and water was taken freely 16 hours before the experiment. Orally administered Mucosolvan and different doses of protein BD-10 (administration volume 10 ml/kg) in groups, and the solvent control group was given the same volume of distilled water. One hour later, 2.5% phenol red solution was injected intraperitoneally. Mice were sacrificed by neck dislocation after 30 minutes. Take a trachea from below the thyroid cartilage to the branch of the trachea, and put the trachea into 3 ml 5% NaHCO.sub.3 solution and let it stand for 3 hours. Take 1 ml of the supernatant and centrifuge at 3000 rpm for 5 minutes. Measure and record the absorbance at 546 nm. According to the standard curve of phenol red, the excretion of phenol red was calculated.

Data Processing:

[0226] Record the time point of oral administration, the time point of intraperitoneal injection of 2.5% phenol red solution, and the time point of taking the trachea respectively; The absorbance of each group of samples was measured by the microplate reader at 546 nm, Calculate the excretion of phenol red according to the standard curve of phenol red. Calculate the mean and standard error of the data in each group, and use TTEST to compare the solvent control group with other groups, and P<0.05 is considered as a significant difference.

Experimental Results:

[0227] Give Mucosolvan (30 mg/kg) and different doses of protein BD-10 (20 mg/kg, 50 mg/kg). One hour later, 2.5% phenol red solution was intraperitoneally injected, and 30 minutes later, the mice were sacrificed by neck dislocation. Take the trachea from below the thyroid cartilage to the branch of the trachea, put the trachea into 3 ml of 5% NaHCO.sub.3 solution and let it stand for 3 hours, take 1 ml of supernatant, centrifuge at 3000 rpm for 5 minutes, measure and record the absorbance at 546 nm. According to the standard curve of phenol red, the excretion of phenol red was calculated. The results are shown in Table 7.

TABLE-US-00011 TABLE 7 The effect of the test drug on the expectorant effect of the phenol red excretion method in mice (X ± SEM) Group N Phenol red excretion (μg/ml) P Solvent control group 10 0.506 ± 0.040  — Mucosolvan 30 mg/kg 10 1.061 ± 0.117** 0.001 BD-10-20 mg/kg 10 0.746 ± 0.035** 0.001 BD-10-50 mg/kg 10 0.668 ± 0.063*  0.042 (Compared with the solvent control group, *P < 0.05, **P < 0.01)

Experimental Results:

[0228] 1) The experimental results showed that compared with the solvent control group, the amount of phenol red excretion in the Mucosolvan 30 mg/kg group was significantly increased, P<0.05, which was statistically significant. [0229] 2) Compared with the solvent control group, the BD-10 20 mg/kg and 50 mg/kg dose groups significantly increased the excretion of phenol red, P<0.05, which was statistically significant.

Experimental Example 6 the Effect of Protein BD-10 (Example 4 Protein) on the Antitussive Effect of the Cough Induced by Ammonia Water in Mice

[0230] Animals: male ICR mice;
Drugs and reagents: dextromethorphan hydrobromide, ammonia water, 0.2% CMC-Na, protein BD-10;
Apparatus: Compressed nebulizer (403T type), balance (XS105DU type).
Experiment grouping: [0231] Solvent control group; [0232] Dextromethorphan 15 mg/kg group; [0233] Protein BD-10, 20 mg/kg group, 50 mg/kg group.

Method:

Model Preparation and Administration:

[0234] Dextromethorphan and different doses of protein BD-10 (administration volume 10 ml/kg) were given orally in groups, and the solvent control group was given the same volume of distilled water. One hour later, mice were put into a sealed box and atomized 10% ammonia water for 10 seconds, and then observed and recorded the incubation period of cough in mice and the number of coughs in 2 minutes.

Data Processing:

[0235] Record the time point of oral administration, the time point of atomization experiment, the incubation period of mice cough and the number of coughs within 2 minutes, respectively. The incubation period of cough refers to the number of seconds from the start of the atomization of ammonia to the occurrence of cough. The performance of coughing in mice is based on contraction of their abdominal muscles (breast contraction) and opening their mouths at the same time. Calculate the mean and standard error of each group of data, and use TTEST to compare the model group with other groups, and P<0.05 is considered as a significant difference.

Experimental Results:

[0236] Give dextromethorphan (15 mg/kg) and different doses of protein BD-10 (20 mg/kg, 50 mg/kg) in advance, One hour later, the mice were put into a sealed box and atomized 10% ammonia water for 10 seconds, and then the mice were observed and recorded the incubation period of coughing and the number of coughs within 2 minutes. The results are shown in Table 8.

TABLE-US-00012 TABLE 8 Antitussive effect experiment of tested drugs on mice cough induced by ammonia water (X ± SEM) Incubation Number Group N period (s) P of coughs P Solvent control group 9 26.9 ± 2.3 — 67.1 ± 5.7 — Dextromethorphan 15 9  38.4 ± 4.5* 0.037  34.0 ± 2.9** 0.001 mg/kg BD-10-20 mg/kg 9 31.4 ± 2.6 0.206 55.3 ± 4.2 0.114 BD-10-50 mg/kg 9 29.4 ± 3.0 0.505 59.8 ± 3.9 0.303 (Compared with the solvent control group, *P < 0.05, **P < 0.01)

Experimental Results:

[0237] 1) The experimental results showed that the dextromethorphan group had a significant improvement in the incubation period and the number of coughs compared with the solvent control group, P<0.05, which was statistically significant. [0238] 2) BD-10 has a tendency to prolong the incubation period and reduce the number of coughs, but there is no statistically significant.

Experimental Example 7 the Pharmacodynamic Test of Protein BD-10 (Example 4 Protein) on Acetic Acid Writhing in ICR Mice

[0239] Animals: male ICR mice;
Drugs and reagents: aspirin, physiological saline, glacial acetic acid, protein BD-10.
Experiment grouping: [0240] Model group; [0241] Aspirin 300 mg/kg group; [0242] Protein BD-10, 50 mg/kg group, 200 mg/kg group.

Method:

[0243] One day after the experimental animals adapt to the environment, Aspirin 300 mg/kg, protein BD-10 50 mg/kg, 200 mg/kg were given orally one hour in advance, and the administration volume was 10 ml/kg; Then, 0.6% acetic acid solution was injected intraperitoneally, and the incubation period (seconds) and frequency of writhing in the animal was observed within 15 minutes.

Data Processing:

[0244] Calculate the mean and standard error of the data in each group. Compared with the model group by TTEST, P<0.05 was considered as statistically different.

Experimental Results:

[0245] One hour after oral administration of aspirin 300 mg/kg and different doses of protein BD-10 (50 mg/kg, 200 mg/kg), 0.6% acetic acid solution was intraperitoneally injected to observe the writhing incubation period and frequency of ICR mice. The results are shown in Table 9.

TABLE-US-00013 TABLE 9 The effects of the tested drugs on the acetic acid writhing test of ICR mice Writhing incubation Frequency of Weight period writhing Group N (g) (seconds) (times) Model group 0.6% 18 22.8 ± 0.2 204.2 ± 19.6 33.3 ± 2.5 acetic acid aspirin 300 mg/kg 13 23.2 ± 0.2  290.3 ± 37.0*   15.2 ± 2.9*** BD-10-50 mg/kg 13 24.1 ± 0.3 237.4 ± 44.8  22.7 ± 3.9* BD-10-200 mg/kg 13 23.7 ± 0.4 251.2 ± 43.3   19.8 ± 3.7 ** (Compared with the model group, ** P < 0.01)

Experimental Results:

[0246] 0.6% acetic acid solution was injected into the abdominal cavity of mice, which caused deep and large area and long-term painful stimulation, causing the mice to writhe (the abdomen was contracted into an “S” shape, the trunk and hind legs were stretched, the buttocks were raised and creeping). The incubation time to start writhing and times of writhing in mice were used as the pain response indexs to determine whether the test sample had analgesic effect. The results of this experiment show: [0247] 1) Aspirin 300 mg/kg can significantly delay the incubation period of writhing and reduce the times of writhing, and has a certain analgesic effect. Compared with the model group, P<0.05, which is statistically significant. [0248] 2) BD-10 50 mg/kg and 200 mg/kg dose groups can significantly reduce the number of writhing mice. Compared with the model group, P<0.05, which is statistically significant.